DexCom, Inc.

DXCM Healthcare Medical Devices

DexCom, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 15.6% from fiscal 2024.

Revenue
+11.2%
EPS
0.00%
Free cash flow
−52.9%
Total debt
+0.31%

Quarter to September 2026, against a year earlier

79.96 4.50 −5.33%
Market cap
$31.5B
P/E
32.6×
Fwd P/E
31.8×
Dividend yield
—
F-score
8/9
Altman Z
6.43
Beneish M
−2.70
Dividend safety
n/a

DexCom, Inc. (DXCM) P/B ratio

Alert me on P/B ratio

As of 5 November 2026, DexCom, Inc. (DXCM) trades at a P/B ratio of 12.5×. Over the past ten years it has ranged from 7.5× (April 2026) to 47.5× (September 2015); the current reading is higher than 14% of that period. That is above the Medical Devices industry median of 2.5× and above the Healthcare sector median of 2.3×.

P/B ratio, daily

Embed this chart

Annual newest first

Period P/B ratio Change
FY2025 9.4× (35.22%)
FY2024 14.6× (36.62%)
FY2023 23.0× 9.60%
FY2022 21.0× (17.60%)
FY2021 25.4× 33.14%
FY2020 19.1× (15.40%)
FY2019 22.6× 41.74%
FY2018 15.9× 33.48%
FY2017 11.9× (30.43%)
FY2016 17.2× (41.95%)

Quarterly newest first

Period P/B ratio Change
Sep 2026 12.8× 29.87%
Jun 2026 9.8× 20.06%
Mar 2026 8.2× (13.28%)
Dec 2025 9.4× (2.31%)
43 more quarters

Against its own ten years

Low 7.5× High 47.5×
Ten-year median 20.3×
Current reading's percentile 16

P/B ratio against peers

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

More on DXCM